Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2825 Airview Blvd KALAMAZOO MI 49002 |
Tel: | N/A |
Website: | https://www.stryker.com |
IR: | See website |
Key People | ||
Kevin A. Lobo Chairman of the Board, President, Chief Executive Officer | Robert S. Fletcher Vice President, Chief Legal Officer | Glenn S. Boehnlein Chief Financial Officer, Vice President |
Viju S. Menon Group President - Global Quality and Operations | J. Andrew Pierce Group President - MedSurg and Neurotechnology | Spencer S. Stiles Group President - Orthopaedics and Spine |
M. Kathryn Fink Chief Human Resource Officer, Vice President | William E. Berry Chief Accounting Officer, Vice President | Aman Rishi Vice President; General Manager, India | Yin C. Becker Vice President - Communications, Public Affairs and Corporate Marketing |
Business Overview |
Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. The Company operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Stryker is also engaged in the design and development of neurointerventional devices for the treatment of intracranial aneurysms. Stryker's geographical segments include the United States and the International. |
Financial Overview |
For the fiscal year ended 31 December 2023, Stryker Corp revenues increased 11% to $20.5B. Net income increased 34% to $3.17B. Revenues reflect MedSurg and Neurotechnology segment increase of 12% to $11.84B, Orthopaedics and Spine segment increase of 11% to $8.66B, United States segment increase of 10% to $6.19B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 11% to $2.62B, Other countries segment increase of 17% to $677M. |
Employees: | 52,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $146,347M as of Dec 31, 2023 |
Annual revenue (TTM): | $20,498M as of Dec 31, 2023 |
EBITDA (TTM): | $5,369M as of Dec 31, 2023 |
Net annual income (TTM): | $3,165M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,997M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $9,942M as of Dec 31, 2023 |
Shares outstanding: | 380,469,830 as of Mar 11, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |